Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. - Test2 - elhamkhani - TriplyDB

Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells.

Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells.

http://www.wikidata.org/entity/Q33526549

about

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu Focus on adoptive T cell transfer trials in melanoma Genetically modified T cells in cancer therapy: opportunities and challenges The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8+T Cell Anti-tumor Activity.The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.Addition of interleukin-21 for expansion of T-cells for adoptive immunotherapy of murine melanoma Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy.Cancer immunotherapy: Progress and challenges in the clinical setting.Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape T cells expanded in presence of IL-15 exhibit increased antioxidant capacity and innate effector molecules.IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells.Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer.Expansion of T Cells with Interleukin-21 for Adoptive Immunotherapy of Murine Mammary Carcinoma Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.Adoptive T-cell transfer in melanoma.Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors.Exploiting cytokines in adoptive T-cell therapy of cancer.Adoptive Cellular Therapy (ACT) for Cancer Treatment.TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells.Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor.T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.Dendritic cell immunotherapy.Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line.

P2860

Q21131200-6268AA8D-E4F4-4595-BF8D-0FD855B81A52 Q21328679-B998EC43-EE42-4E28-A2E9-1699E6802DE9 Q27026627-4F973ECB-924E-49CC-9678-4224B7106C96 Q33633272-070DC75B-ACCD-4CFE-8529-00EDAC567523 Q33670728-A90A996F-D896-4A96-B692-25D846F95856 Q34256494-2BF5DF45-1E77-4AF7-9664-0055DFC26249 Q35585735-9D1B6D43-3F1A-4B1A-B19C-38697AB1F6E4 Q35752854-E0C0BB90-C517-4CBF-AB98-B01AFF6F46CE Q36184314-6A552576-98ED-4A59-90D1-FA63C8655B36 Q36321054-AE4A5363-C141-4EB4-B63A-CD8DC876092C Q36678607-791D103B-B148-45E0-B661-BE595B8C3862 Q36767295-495260C7-AAC3-47A6-8BFD-87F8BBD14CEE Q36871188-142EFD59-AC81-438F-917C-0D1440B1D92C Q37233539-D45A4FCF-B285-428F-A5F1-3673ABF1AE70 Q37690690-BCEDC723-FA0B-4C40-8457-B3D9A9CD676C Q37861192-AAA41ADD-D252-4335-984B-BFBEE2CD9DF8 Q38068968-F783AEA6-2E25-4929-B8C1-A2588542F24E Q38525034-11E50A83-BBD7-4C00-8CE8-40AF790D92DE Q38525044-08CCED57-2CA6-4CF8-966E-12F94E8F8809 Q38848219-DA8A8700-BE93-42F9-8941-2C894D0D6619 Q39383424-B3D61FCB-ABE1-476B-9003-BB29BDE2F1F9 Q40095245-A8C7902A-B593-413A-B78D-0DB65DAF6DA6 Q41069286-007C683A-836E-46D1-8051-CB85A7D674A2 Q42552126-C517F673-5F01-4E5A-A760-7E925C5797F3 Q44483910-8F86B0FB-DE41-4346-B59A-4FDE69C58C30 Q45872592-06500311-F20B-4F5D-A8B2-B49732C30E73

P2860

Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells.

http://www.wikidata.org/entity/Q33526549

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Combination of IL-21 and IL-15 ...... CR-transduced primary T cells.

@ast

Combination of IL-21 and IL-15 ...... CR-transduced primary T cells.

@en

Combination of IL-21 and IL-15 ...... CR-transduced primary T cells.

@nl

type

label

Combination of IL-21 and IL-15 ...... CR-transduced primary T cells.

@ast

Combination of IL-21 and IL-15 ...... CR-transduced primary T cells.

@en

Combination of IL-21 and IL-15 ...... CR-transduced primary T cells.

@nl

prefLabel

Combination of IL-21 and IL-15 ...... CR-transduced primary T cells.

@ast

Combination of IL-21 and IL-15 ...... CR-transduced primary T cells.

@en

Combination of IL-21 and IL-15 ...... CR-transduced primary T cells.

@nl

P1433

Q33526549-F60F344B-87F5-442C-A1AA-9999FFFD4E77

P1476

Q33526549-72E0C54C-A198-4CAE-98A3-726AF521ED6D

P2093

Q33526549-13A8D47E-7287-4781-B572-FB8E9E4371EC

Q33526549-32AF6C91-0632-49FD-ABD9-47F7B869B5A4

Q33526549-4171BDAC-3066-480C-8D1C-19A196E4D1BD

Q33526549-710CE2E2-5930-48B9-9986-B7C98DB9B147

Q33526549-81D5E973-D666-4DEA-A202-2C8502A82194

Q33526549-94DD16AB-A98E-48AF-87C5-87A5E1ECA91E

P2860

Q33526549-03CD5263-EAD9-4501-95D9-FD5F4CCC46DB

Q33526549-49D79521-0DD0-4B7A-A07F-34732ECA3984

Q33526549-4C1F1CCA-743C-44C4-B8ED-8D9600CE00ED

Q33526549-55E548A0-8F29-4831-B066-2E52CE187762

Q33526549-573DF1D0-C03D-4C50-B1F8-F7445D549963

Q33526549-8870F204-5FC6-4CD2-9E99-9DAC217FA123

Q33526549-8EC99266-ABD6-491A-8298-79BAB272741D

P2888

Q33526549-E02E15EA-CC9E-4BD2-91AD-CA07751EAEE7

P304

Q33526549-1D96F25E-7F73-4AAF-B741-5A8AAD5120EE

P31

Q33526549-DF7A8610-8C42-46BC-B23E-D3B09111C33B

P356

Q33526549-E5FDF29B-31D8-4966-B582-ADDCE02CF2C3

P433

Q33526549-15EBF63B-37ED-4252-A4A1-CBF5057FB30E

P478

Q33526549-2BFA089C-5C02-4628-86A6-95952E08DCC1

P50

Q33526549-0AB1C02D-785D-4387-9779-E63F2F346F47

P577

Q33526549-1C8C66FC-0339-4CE4-B404-539521C9F0D9

P5875

Q33526549-EE2ED2E9-C45F-4E95-A34C-83EEFE027C5B

P6179

Q33526549-7A866039-E9B9-440A-8C80-311F47B7FF48

P698

Q33526549-686127F1-D219-4EBA-99DE-39ECDD4FC12D

P921

Q33526549-D9E10FDB-D127-45FC-8887-E4B7BA89144F

P356

S00262-010-0818-0

P1433

Cancer Immunology, Immunotherapy

P1476

Combination of IL-21 and IL-15 ...... CR-transduced primary T cells.

@en

P2093

Elike Treffers-Westerlaken

http://www.w3.org/2001/XMLSchema#string

Floyd Wittink

http://www.w3.org/2001/XMLSchema#string

Jaap Verweij

http://www.w3.org/2001/XMLSchema#string

Nadine Pouw

http://www.w3.org/2001/XMLSchema#string

Reno Debets

http://www.w3.org/2001/XMLSchema#string

Timo ten Hagen

http://www.w3.org/2001/XMLSchema#string

P2860

IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells

IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response

IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21

Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.

Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine.

Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy

IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.

P2888

s00262-010-0818-0

P304

921-931

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-010-0818-0

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41139812

http://www.w3.org/2001/XMLSchema#string

P6179

1047155853

http://www.w3.org/2001/XMLSchema#string

P698

20101507

http://www.w3.org/2001/XMLSchema#string

P921